We operate as a 501c3 non-profit: combining the optimal entrepreneurial practices of a for profit biotech and pharmaceutical company with the passion and urgency of a nonprofit mission.
We have pushed more potential treatments for ALS through preclinical evaluations than the rest of the ALS field worldwide combined. Our screening platform is seen as the gold-standard for most grant-makers and our discovery program is unrivaled across all of neurodegeneration. We collaborate with dozens of partners in academia and industry on drug development, target validation and clinical biomarker discovery. We have a team of 45 people, 30 of whom are full-time scientists and drug developers.